An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citationReducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Self-citationProbing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Self-citationGetting pharmaceutical R&D back on target
Bunnage, M. E. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.581 · Cited by 258
The influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
Self-citationA quantitative assessment of hERG liability as a function of lipophilicity
Waring, M. J., & Johnstone, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.061 · Cited by 159
Self-citationPeters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 156
Morphy, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512185 · Cited by 123
Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs
Vieth, M., & Sutherland, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603825 · Cited by 103
Inflation of correlation in the pursuit of drug-likeness
Kenny, P. W., & Montanari, C. A. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9631-5 · Cited by 81
PHYSICOCHEMICAL AND CELL-BASED APPROACH FOR EARLY SCREENING OF PHOSPHOLIPIDOSIS-INDUCING POTENTIAL
Tomizawa, K., Sugano, K., Yamada, H., & HORII (2006) · The Journal of Toxicological Sciences · doi:10.2131/jts.31.315 · Cited by 78
Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules
Luker, T. J., Alcaraz, L., Chohan, K. K., Blomberg, N., Brown, D. S., Butlin, R. J., Elebring, T., Griffin, A. M., Guile, S. D., St-Gallay, S. A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.074 · Cited by 60
Self-citationSutherland, J. J., Raymond, J. W., Stevens, J. L., Baker, T. K., & Watson, D. E. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300684u · Cited by 58
Wager, T. T., Kormos, B. L., Brady, J. T., Will, Y., Aleo, M. D., Stedman, D. B., Kühn, M., & Chandrasekaran, R. Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401485p · Cited by 45
A critical assessment of modeling safety-related drug attrition
Muthas, D., Boyer, S. K., & Hasselgren, C. (2013) · MedChemComm · doi:10.1039/c3md00072a · Cited by 39
Accurate In Silico log P Predictions: One Can't Embrace the Unembraceable
Tetko, I. V., Poda, G. I., Ostermann, C., & Mannhold, R. (2009) · QSAR & Combinatorial Science · doi:10.1002/qsar.200960003 · Cited by 38
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab255 · Cited by 2,857
A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
Daina, A., & Zoete, V. (2016) · ChemMedChem · doi:10.1002/cmdc.201600182 · Cited by 2,549
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
Self-citationOpportunities and obstacles for deep learning in biology and medicine
Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., Ferrero, E., Agapow, P.-M., Zietz, M., Hoffman, M. M., et al. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0387 · Cited by 2,310
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.